Skip to main content

A Gray Zone in Thyroid Fine-Needle Aspiration Cytology: AUS-FLUS

  • Chapter
  • First Online:
Thyroid and Parathyroid Diseases

Abstract

Thyroid nodules are a common finding in the adult population. Fine-needle aspiration biopsy (FNAB), when required, has an important role in the assessment of a thyroid nodule by assisting the triage of patients to surgery or surveillance. However, FNABs which are classified in the Bethesda category 3 (atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS)) are difficult to manage because of the wide spectrum of cytopathologic findings in this category. While the Bethesda System for Reporting Thyroid Cytopathology recommends repeat FNAB for category 3, recent studies recommend molecular testing, if available. And also, surveillance or surgery is recommended especially if repeat FNAB cytology and/or molecular testing is not performed or inconclusive. In conclusion, unlike other categories in Bethesda classification, management of the AUS/FLUS category is still controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kiernan CM, Solórzano CC. Bethesda category III, IV, and V thyroid nodules: can nodule size help predict malignancy? J Am Coll Surg. 2017;225:77–82.

    Article  Google Scholar 

  2. Russ G, Leboulleux S, Leenhardt L, Hegedus L. Thyroid incidentalomas: epidemiology, risk stratification with ultrasound and workup. Eur Thyroid J. 2014;3:154–63.

    Article  Google Scholar 

  3. Polyzos SA, Kita M, Avramidis A. Thyroid stepwise diagnosis and management. Hormones. 2007;6:101–19.

    Article  Google Scholar 

  4. Cibas ES, Ali SZ, NCI Thyroid FNA State of the Science Conference. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132:658–65.

    Article  Google Scholar 

  5. Estrada Muñoz L, Díaz Del Arco C, Ortega Medina L, Fernández Aceñero MJ. Thyroid atypia/follicular lesion of undetermined significance: attitudes towards the diagnosis of Bethesda system III nodules. Acta Cytol. 2017;61:21–6.

    Article  Google Scholar 

  6. Cohen O, Tzelnick S, Lahav Y, Schindel D, Halperin D, Yehuda M. Selection of atypia/follicular lesion of unknown significance patients for surgery versus active surveillance, without using genetic testing: a single institute experience, prospective analysis, and recommendations. Thyroid. 2017;27:928–35.

    Article  Google Scholar 

  7. Kholova I, Ludvikova M. Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage? Acta Cytol. 2014;58:319–29.

    Article  Google Scholar 

  8. Kim SK, Hwang TS, Yoo YB, Han HS, Kim DL, Song KH, et al. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status. J Clin Endocrinol Metab. 2011;96:658–64.

    Article  CAS  Google Scholar 

  9. Carr R, Ustun B, Chhieng D, Schofield K, Theoharis C, Hammers L, et al. Radiologic and clinical predictors of malignancy in the follicular lesion of undetermined significance of the thyroid. Endocr Pathol. 2013;24:62–8.

    Article  Google Scholar 

  10. Crowe A, Linder A, Hameed O, Salih C, Roberson J, Gidley J, et al. The impact of implementation of the Bethesda system for reporting thyroid cytopathology on the quality of reporting, “risk” of malignancy, surgical rate, and rate of frozen sections requested for thyroid lesions. Cancer Cytopathol. 2011;119:315–21.

    Article  Google Scholar 

  11. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56:333–9.

    Article  Google Scholar 

  12. Topaloglu O, Baser H, Cuhaci FN, Sungu N, Yalcin A, Ersoy R, et al. Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda Category III (AUS/FLUS) in cytology. Endocrine. 2016;54:156–68.

    Article  CAS  Google Scholar 

  13. Gocun PU, Karakus E, Bulutay P, Akturk M, Akin M, Poyraz A. What is the malignancy risk for atypia of undetermined significance?. Three years’ experience at a university hospital in Turkey. Cancer Cytopathol. 2014;122:604–10.

    Article  Google Scholar 

  14. Park HJ, Moon JH, Yom CK, Kim KH, Choi JY, Choi SI, et al. Thyroid “atypia of undetermined significance” with nuclear atypia has high rates of malignancy and BRAF mutation. Cancer Cytopathol. 2014;122:512–20.

    Article  CAS  Google Scholar 

  15. Turkyilmaz S, Ulusahin M, Celebi B, Cekic AB, Mungan S, Kucuktulu U, et al. Thyroid nodules classified as atypia or follicular lesions of undetermined significance deserve further research: analysis of 305 surgically confirmed nodules. Cytopathology. 2017;28:391–9.

    Article  CAS  Google Scholar 

  16. Vanderlaan PA, Krane JF, Cibas ES. The frequency of ‘atypia of undetermined significance’ interpretations for thyroid fine-needle aspirations is negatively correlated with histologically proven malignant outcomes. Acta Cytol. 2011;55:512–7.

    Article  Google Scholar 

  17. Rosario PW, Calsolari MR. Importance of cytological subclassification of thyroid nodules with Bethesda category III cytology (AUS/FLUS) into architectural atypia only and nuclear atypia: a prospective study. Diagn Cytopathol. 2017;45(7):604.

    Article  Google Scholar 

  18. Gan TR, Nga ME, Lum JH, Wong WM, Tan WB, Parameswaran R, et al. Thyroid cytology-nuclear versus architectural atypia within the "atypia of undetermined significance/follicular lesion of undetermined significance" Bethesda category have significantly different rates of malignancy. Cancer. 2017;125:245–56.

    Google Scholar 

  19. Chandra S, Chandra H, Bisht SS. Malignancy rate in thyroid nodules categorized as atypia of undetermined significance or follicular lesion of undetermined significance: an institutional experience. J Cytol. 2017;34:144–8.

    Article  Google Scholar 

  20. Kim SD, Han SH, Jeong WJ, Kim H, Ahn SH. Differences in clinical features between subcategories of “atypia/follicular lesion of undetermined significance”. Endocr Pathol. 2017;28:247–52.

    Article  Google Scholar 

  21. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.

    Article  Google Scholar 

  22. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390–7.

    Article  CAS  Google Scholar 

  23. Cantara S, Capezzone M, Marchisotta S, Capuano S, Busonero G, Toti P, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365–9.

    Article  CAS  Google Scholar 

  24. Labourier E, Shifrin A, Busseniers AE, Lupo MA, Manganelli ML, Andruss B, et al. Molecular testing for miRNA, mRNA, and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology. J Clin Endocrinol Metab. 2015;100:2743–50.

    Article  CAS  Google Scholar 

  25. Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, et al. Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance/follicular lesion of undetermined significance cytology. Thyroid. 2015;25:1217–23.

    Article  CAS  Google Scholar 

  26. Lithwick-Yanai G, Dromi N, Shtabsky A, Morgenstern S, Strenov Y, Feinmesser M, et al. Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smears. J Clin Pathol. 2017;70:500–7.

    Article  CAS  Google Scholar 

  27. Wu JX, Lam R, Levin M, Rao J, Sullivan PS, Yeh MW. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. Surgery. 2016;159:118–26.

    Article  Google Scholar 

  28. Kwak JY, Han KH, Yoon JH, Moon HJ, Son EJ, Park SH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011;260:892–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Ali Koç, M., Demirer, S., Kocaay, A.F. (2019). A Gray Zone in Thyroid Fine-Needle Aspiration Cytology: AUS-FLUS. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-78476-2_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-78475-5

  • Online ISBN: 978-3-319-78476-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics